Skip to content

Study of antibodies in Babies born to mothers who are recovered from COVID 19

A prospective Observation study to see the trends of SARS COVID 19 antibodies in newborns of seropositive mothers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034057
Enrollment
50
Registered
2021-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: O989- Unspecified maternal infectious and parasitic disease complicating pregnancy, childbirth and the puerperium

Interventions

None listed

Sponsors

Sparsh Hospital Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All pregnant women who are infected with COVID 19 during the gestation period

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
1. To study the rate of transmission of maternal COVID Ig G antibodies to the neonate. 2. To study the trend of maternally transmitted COVID Ig G antibodies in the neonate over the first seventy five days of life. Timepoint: first 75 days after the birth in a newborn.

Secondary

MeasureTime frame
1.To study the correlation of the COVID Ig G antibody levels to the duration since confirmed disease. 2. To study the correlation of the COVID Ig G levels to the severity of the covid disease. 3. To study the correlation of COVID Ig G levels to the duration since vaccination and the type of COVID vaccine used. 4. To study the correlation of COVID Ig G levels to the interval between vaccine doses. Timepoint: follow up time till 75 Days after the delivery

Countries

India

Contacts

Public ContactJohn Paul

Sparsh super speciality Hospital

drjohnpaulm@gmail.com8197290730

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026